These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37491871)

  • 1. Acute kidney injury in patients with cancer receiving anti-PD-1/PD-L1 antibodies: incidence, risk factors, and prognosis.
    Lou Q; Gong J; Ye B; Yu R; Bu S; Li Y; Zhu B; Shao L
    Ren Fail; 2023 Dec; 45(1):2238823. PubMed ID: 37491871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of acute kidney injury by initiation of non-steroidal anti-inflammatory drugs in hospitalised patients treated with diuretics and renin-angiotensin-aldosterone system inhibitors.
    Bories M; Bacle A; Gilardi H; Le Corre P
    Eur J Hosp Pharm; 2022 Nov; 29(6):359-361. PubMed ID: 33478983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute kidney injury associated with anti-PD-1 and anti-PD-L1 drugs: a meta-analysis of randomized clinical trials.
    Lima IG; Silva IBUCD; Pípolo VC; Delfino VDA; Bignardi PR
    Immunopharmacol Immunotoxicol; 2024 Aug; 46(4):470-481. PubMed ID: 38825890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-steroidal anti-inflammatory drugs, renin-angiotensin system blockade or diuretics and risk of acute kidney injury: A case-crossover study.
    Weng SE; Hsu WT; Hsiao FY; Lee CM
    Arch Gerontol Geriatr; 2024 Aug; 123():105394. PubMed ID: 38537386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study.
    Liu K; Qin Z; Ge Y; Bian A; Xu X; Wu B; Xing C; Mao H
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5061-5070. PubMed ID: 36326913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study.
    Ji MS; Wu R; Feng Z; Wang YD; Wang Y; Zhang L; Sun XF; Chen XM; He KL; Cai GY
    Sci Rep; 2022 Nov; 12(1):18752. PubMed ID: 36335144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time until onset of acute kidney injury by combination therapy with "Triple Whammy" drugs obtained from Japanese Adverse Drug Event Report database.
    Kunitsu Y; Hira D; Morikochi A; Ueda T; Isono T; Morita SY; Terada T
    PLoS One; 2022; 17(2):e0263682. PubMed ID: 35139129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury.
    Dreischulte T; Morales DR; Bell S; Guthrie B
    Kidney Int; 2015 Aug; 88(2):396-403. PubMed ID: 25874600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
    Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
    Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
    Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
    Front Immunol; 2020; 11():624547. PubMed ID: 33552089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
    Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.
    Cortazar FB; Kibbelaar ZA; Glezerman IG; Abudayyeh A; Mamlouk O; Motwani SS; Murakami N; Herrmann SM; Manohar S; Shirali AC; Kitchlu A; Shirazian S; Assal A; Vijayan A; Renaghan AD; Ortiz-Melo DI; Rangarajan S; Malik AB; Hogan JJ; Dinh AR; Shin DS; Marrone KA; Mithani Z; Johnson DB; Hosseini A; Uprety D; Sharma S; Gupta S; Reynolds KL; Sise ME; Leaf DE
    J Am Soc Nephrol; 2020 Feb; 31(2):435-446. PubMed ID: 31896554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
    Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
    Front Immunol; 2020; 11():574271. PubMed ID: 33162990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
    Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors.
    Seethapathy H; Zhao S; Strohbehn IA; Lee M; Chute DF; Bates H; Molina GE; Zubiri L; Gupta S; Motwani S; Leaf DE; Sullivan RJ; Rahma O; Blumenthal KG; Villani AC; Reynolds KL; Sise ME
    Kidney Int Rep; 2020 Oct; 5(10):1700-1705. PubMed ID: 33102962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence, risk factors, and clinical outcomes of acute kidney injury (staged using the RIFLE classification) associated with intravenous acyclovir administration.
    Lee EJ; Jang HN; Cho HS; Bae E; Lee TW; Chang SH; Park DJ
    Ren Fail; 2018 Nov; 40(1):687-692. PubMed ID: 30741619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
    Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
    BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diuretics associated acute kidney injury: clinical and pathological analysis.
    Wu X; Zhang W; Ren H; Chen X; Xie J; Chen N
    Ren Fail; 2014 Aug; 36(7):1051-5. PubMed ID: 24940940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.
    Seethapathy H; Zhao S; Chute DF; Zubiri L; Oppong Y; Strohbehn I; Cortazar FB; Leaf DE; Mooradian MJ; Villani AC; Sullivan RJ; Reynolds K; Sise ME
    Clin J Am Soc Nephrol; 2019 Dec; 14(12):1692-1700. PubMed ID: 31672794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute Kidney Injury in COVID-19 Patients: An Inner City Hospital Experience and Policy Implications.
    Zahid U; Ramachandran P; Spitalewitz S; Alasadi L; Chakraborti A; Azhar M; Mikhalina G; Sherazi A; Narh JT; Khattar P; Bedi P
    Am J Nephrol; 2020; 51(10):786-796. PubMed ID: 33011717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.